# Panacea Intelligence OS

## Product thesis

Panacea should not compete as another biomarker subscription, wearable dashboard, peptide storefront, or concierge clinic. The product should be an intelligence-first operating layer that connects longitudinal health data, evidence, clinicians, diagnostics, care workflows, interventions, and outcomes.

Core loop:

`data → understanding → decision support → clinician review → care → intervention → measurement → outcome → learning`

The moat is the closed loop and its governance, not the number of biomarkers on a landing page.

## 1. Panacea Health Graph

The Health Graph is the canonical longitudinal model of a person. It joins history, diagnoses, medications, labs, imaging, wearables, symptoms, lifestyle, genomics where appropriately verified, clinician decisions, and measured outcomes.

Coverage is descriptive only:

`coverage = observed domains / supported domains × 100%`

Coverage must never be presented as health status, risk, prognosis, biological age, or a clinical score.

## 2. Evidence Engine

Every clinically meaningful claim or intervention is assigned a visible evidence tier:

- **A — Established:** strong guideline, synthesis, or consistent randomized evidence.
- **B — Supported:** moderate-quality or guideline-supported evidence with limitations.
- **C — Emerging:** promising but incomplete evidence; discussion/review only.
- **D — Experimental:** research-stage; no autonomous patient action.
- **X — Insufficient / unsafe:** blocked from clinical recommendation surfaces.

Product governance rule:

- D remains research-only.
- X is blocked.
- C requires clinician review for any clinical use.
- Patient-specific A/B outputs still require clinician review before clinical action unless a separately validated, regulated workflow explicitly permits otherwise.

This is a software publication and workflow gate, not a treatment guideline.

## 3. Precision diagnostics and care orchestration

Panacea should progressively recommend the next information source only when justified by evidence and context. The product surface should expose:

- reason for considering the test or service;
- expected information gain;
- evidence strength;
- cost and access context;
- possible harms, false positives, or downstream burden;
- clinician-review status.

The sequence is:

`structured intake → longitudinal context → evidence review → clinician decision → investigation/service → result ingestion → follow-up measurement`

## 4. Body Exposure as the explanatory interface

Body Exposure should become the visual interface over the Health Graph rather than a disconnected anatomy showcase. It can connect anatomy, physiology, pathophysiology, pharmacology, imaging, symptoms, labs, and interventions while preserving the distinction between:

- measured;
- derived;
- simulated;
- reference;
- research-only;
- unsupported.

Generic atlas geometry must never be represented as patient-specific anatomy.

## 5. Revenue architecture

Panacea should share one intelligence layer across several revenue engines:

1. **Panacea Free** — acquisition, basic organization, education and discovery.
2. **Panacea Core** — consumer subscription for Health Graph, integrations, summaries and longitudinal intelligence.
3. **Panacea Precision** — diagnostics/service orchestration with transparent economics where legally permitted.
4. **Panacea Care** — clinician consultation and care-orchestration platform fees.
5. **Panacea Pro** — clinician SaaS: CDSS, evidence, summaries, monitoring and documentation.
6. **Panacea Enterprise** — hospitals, clinics, employers and population-health contracts.
7. **Panacea API** — clinical-intelligence infrastructure and workflow components.
8. **Body Exposure** — professional education, simulation and institutional licensing.

The software layer should remain economically useful even when a user does not purchase a test, consultation, medication, or procedure.

## 6. Business metrics

Planning formulas used in the Architecture workbench:

`LTV ≈ monthly ARPU × gross margin / monthly churn`

`CAC payback months ≈ CAC / monthly contribution margin`

`LTV/CAC = LTV / CAC`

These are planning heuristics. They are not financial forecasts and should not substitute for cohort-based retention, contribution-margin, cash-flow, or regulatory analysis.

## 7. Defensibility flywheel

`more users + clinicians`
→ `richer consented longitudinal data`
→ `better calibrated models/workflows`
→ `more useful decisions/explanations`
→ `better measurable outcomes`
→ `more trust/distribution`
→ repeat.

No identifiable health information should be treated as a resale product. Model improvement and research require appropriate consent, privacy controls, governance, security, auditability, and applicable legal/regulatory review.

## 8. Recommended execution order

1. Canonical Health Graph and provenance model.
2. Evidence Engine and publication/review gates.
3. Body Exposure bridge from graph nodes to understandable anatomy/physiology context.
4. Diagnostics/service orchestration contracts.
5. Clinician workflow and review surfaces.
6. Outcome loop and longitudinal effectiveness monitoring.
7. Consumer and professional monetization on top of the shared intelligence layer.

This sequence keeps Panacea differentiated as an intelligence system rather than a catalog of disconnected health features.
